摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5-二乙基恶唑 | 40953-14-8

中文名称
2,5-二乙基恶唑
中文别名
——
英文名称
2,5-Diethyloxazole
英文别名
2,5-diethyl-1,3-oxazole
2,5-二乙基恶唑化学式
CAS
40953-14-8
化学式
C7H11NO
mdl
——
分子量
125.17
InChiKey
IQWHXRKZJXFLTB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 保留指数:
    903;940;940;909

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    26
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • NITROGEN-CONTAINING HETEROARYL DERIVATIVES
    申请人:Bleicher Konrad
    公开号:US20110183979A1
    公开(公告)日:2011-07-28
    The invention is concerned with novel nitrogen-containing heteroaryl derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.
    本发明涉及式(I)的新氮杂芳基衍生物,其中R1、R2、R3、R4、R5、A1、A2和Y的定义如描述和权利要求中所述,以及这些化合物的生理可接受的盐和酯。这些化合物可以抑制PDE10A,并可作为药物使用。
  • FUSED RING HETEROCYCLE KINASE MODULATORS
    申请人:Chen Chixu
    公开号:US20080261921A1
    公开(公告)日:2008-10-23
    The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.
    本发明提供了融合环杂环化合物作为激酶调节剂,含有这些调节剂的药物组合物,以及使用这些调节剂治疗由激酶活性介导的疾病的方法。
  • PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
    申请人:Cutshall Neil S.
    公开号:US20110224202A1
    公开(公告)日:2011-09-15
    Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.
    揭示了抑制PDE10的化合物,对治疗多种疾病有用,包括(但不限于)精神病、焦虑、运动障碍和/或神经系统疾病,如帕森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑瘫、睡眠障碍、疼痛、抽动综合征、精神分裂症、妄想症、药物诱发的精神病、恐慌和强迫症。还提供了这些化合物的药用盐、立体异构体、溶剂合物和前药。还揭示了含有化合物与药用载体组合的组合物,以及与使用有关的方法,用于在需要的温血动物中抑制PDE10。
  • Hepatitis C Virus Inhibitors
    申请人:Romine Jeffrey Lee
    公开号:US20100215616A1
    公开(公告)日:2010-08-26
    The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    本公开涉及化合物、组合物和治疗丙型肝炎病毒(HCV)感染的方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
  • Anti-Viral Compounds
    申请人:DeGoey David A.
    公开号:US20120004196A1
    公开(公告)日:2012-01-05
    Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    本发明描述了一些有效抑制丙型肝炎病毒(“HCV”)复制的化合物。此发明还涉及制造这些化合物的过程,包含这些化合物的组合物,以及使用这些化合物治疗HCV感染的方法。
查看更多